ImmuneOnco says first PAH patient dosed in Phase Ib/IIa trial of IMC-003

• ImmuneOnco Biopharmaceuticals (Shanghai) dosed the first patient in a Phase Ib/IIa pulmonary arterial hypertension trial of IMC-003.
• Early clinical results were presented, with Phase I single-ascending-dose enrollment completed in postmenopausal healthy women.
• The drug was generally well tolerated, with no serious treatment-related safety signals reported.
• Multiple-ascending-dose enrollment also finished, with early safety described as encouraging; later assessments remain pending.
• IMC-003 targets a pathway addressed by Merck’s Winrevair, positioning the asset for patient-stage validation in PAH.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260825-12298299), on August 25, 2026, and is solely responsible for the information contained therein.